



## Passing of LIXTE Board Member Gil N Schwartzberg



We at LIXTE are deeply saddened to report the passing of Gil N Schwartzberg, one of our Board Members and a co-founder of the company. Dr. John Kovach, CEO of LIXTE Biotechnology Holdings, Inc., and Mr. Schwartzberg founded LIXTE in the hopes of finding better treatments for cancer. Throughout more than 16 years of service, Mr. Schwartzberg's wise counsel, business acumen, and unwavering financial support of the company helped LIXTE grow from concept to compound to Phase 2 clinical testing.

Gil N Schwartzberg, JD, ScD (hon) had been a consultant to LIXTE since its founding and became a member of the LIXTE Board of Directors in 2021. Previously, Mr. Schwartzberg was Chairman of the Board, President and Chief Executive Officer of the City of Hope National Medical Center, one of the nation's leading biomedical research and treatment facilities and a National Cancer Institute (NCI) Comprehensive Cancer Center. Mr. Schwartzberg is the only person in the hundred-plus-year history of City of Hope to have served as both Chairman of the Board and Chief Executive Officer. He also earned the designation of City of Hope Chairman Emeritus for life.

During his extensive career, Mr. Schwartzberg found success across a wide range of industries, holding positions of major responsibility in law, biomedicine, banking, apparel/shoe manufacturing and fast-food retailing. He was a founding shareholder of Skechers USA, Inc. and oversaw the process by which over a dozen companies became publicly traded on all of the US securities exchanges.

Mr. Schwartzberg earned a Juris Doctorate awarded *magna cum laude*. Mr. Schwartzberg practiced law, specializing in business structure and transactions and was a member in good standing of the California Bar. Mr. Schwartzberg is the author of two books: *Warning! Toxic Business Mistakes and How to Avoid Making Them* and *Jane Austen's Persuasion Annotated, a Royal Navy Reading Companion*. LIXTE hopes to honor his tremendous contributions and legacy by fulfilling its mission of discovering and developing drugs for more effective treatments for many forms of cancer and other serious common diseases.